BML-260

Overview

BML-260 is a potent inhibitor of dual-specific phosphatases JSP-1 and DUSP22 . BML-260 can activate UCP1 and thermogenesis in adipocytes in a JSP-1 -independent manner. The effect of BML-260 on adipocytes is partially achieved through the activation of CREB , STAT3 , and PPAR signaling pathways. BML-260 can be used in the research of inflammatory and proliferative disorders associated with JNK signaling dysfunction as well as obesity.

Application

Products | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Pain | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Obesity | Products > Disease Areas > Cancer | Products > Signaling Pathways > JAK/STAT Signaling | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > Vitamin D Related/Nuclear Receptor | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > STAT | Products > Signaling Pathways > PPAR

Product Information

• Catalog No.: HY-133095
• CAS No.: 101439-76-3
• Molecular Formula: C17H11NO3S2
• Molecular Weight: 341.40
• Purity: 99.65%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source